Protalix BioTherapeutics, Inc. (PLX) Return on equity 2023–2025
Protalix BioTherapeutics, Inc. (PLX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-13.7%FY2025 · since FY2023: 24.8% → -13.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -13.7% | -20.5 pp |
| FY2024 | 6.8% | -18.0 pp |
| FY2023 | 24.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice